Ours is the first study to demonstrate CNS GSH augmentation using a noninvasive, self-administered therapy in humans
Geroprotective and Anticarcinogenic Activity Lifetime Murine Studies Long-term studies in mice demonstrated that DSIP administration over a lifetime decreased total spontaneous tumour incidence 2.6-fold compared to untreated controls, slowed age-related switching-off of oestrous function, decreased the frequency of chromosome aberrations in bone marrow cells by 22.6%, and increased maximum lifespan by 24.1% compared to control groups a multi-parameter geroprotective profile that is among the most striking reported for any short regulatory peptide, and that has generated sustained interest in the DSIP analogue research field
For instance, Type IV is suitable for dark skin and Type V is for very dark skin
Silymarin and its major constituent, silibinin, has recently been shown to exert significant anti-neoplastic effects in a variety of in vitro and in vivo cancer models, including skin, breast, lung, colon, bladder, prostate and kidney carcinomas
